JNJ Share Price Pulls Back Amid FDA Approval, but Momentum Suggests Undervaluation
Johnson & Johnson's (JNJ) recent FDA approval for Imaavy has sparked questions among investors. The treatment is specifically cleared for warm autoimmune hemolytic anemia, a rare blood disorder. Despite a short-term share price pullback of around 1% on the day of the announcement, JNJ's recent approvals in wAIHA and atrial fibrillation come against a stronger backdrop.
The company's 90-day share price return is 16.98%, and its 1-year total shareholder return is 56.17%. This indicates momentum that has been building rather than fading. Some analysts flag JNJ as trading below intrinsic value, with a fair value of $246.46 in the most followed narrative.
However, another view on JNJ's valuation presents a different perspective. The SWS DCF model estimates a future cash flow value of $364.27 at its current price of $270. This suggests that JNJ is undervalued instead of overvalued. A 25.88% gap between the two valuations raises questions about whether the market is giving too much weight to recent earnings softness and legal risk.